Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clene's regulatory disclosures and financial reporting.
Clene Inc. received an updated beneficial ownership report from several Vivo Opportunity entities. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC each report beneficial ownership of 1,321,675 shares of common stock on an as-converted basis from Series A, Series B and Tranche B warrants. Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC each report beneficial ownership of 101,936 shares of common stock issuable upon exercise of Series A and Series B warrants. Each reporting person discloses beneficial ownership of 9.99% of Clene’s common stock, with all warrants subject to provisions that block exercises that would raise ownership above 9.99% of the issuer’s voting securities.
Clene Inc. reported that director Matthew Kiernan received a grant of 3,195 stock options for common stock under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and expire on August 12, 2036. Following this grant, Kiernan holds 3,195 derivative securities representing the right to acquire an equal number of common shares.
Clene Inc. director Arjun JJ Desai received a grant of 3,674 stock options on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. Each option has an exercise price of $4.19 per share and is exercisable for common stock. According to the grant terms, the options vest immediately upon grant and expire on August 12, 2036, resulting in post-transaction direct holdings of 3,674 options.
Clene Inc. reported that director Alison Mosca received a grant of 4,872 stock options on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and expire on August 12, 2036, leaving her with 4,872 derivative securities outstanding from this grant.
Clene Inc. director David J. Matlin received a grant of 6,230 stock options on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and are exercisable into 6,230 shares of common stock until August 12, 2036. Following this award, Matlin holds 6,230 stock options directly.
Clene Inc. director Shalom Jacobovitz received a grant of stock options for 4,752 shares of common stock on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and expire on August 12, 2036. Following this award, Jacobovitz holds 4,752 stock options directly.
Clene Inc. director Jonathon Gay received a compensatory grant of 3,794 stock options on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and are exercisable into 3,794 shares of common stock until August 12, 2036. Following this award, Gay holds 3,794 derivative securities directly.
Clene Inc. director Vallerie McLaughlin received a stock option grant for 3,514 shares of common stock on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The option has an exercise price of $4.19 per share, vests immediately upon grant, and expires on August 12, 2036. Following this grant, she holds options for 3,514 shares directly.
Clene Inc. director Reed N. Wilcox reported a grant of stock options for 3,514 shares of common stock on August 13, 2026 under the Clene Inc. Amended 2020 Stock Plan. The options have an exercise price of $4.19 per share, vest immediately upon grant, and expire on August 12, 2036. Following this award, Wilcox holds 3,514 options directly.
Clene Inc. reported second quarter 2026 results and highlighted regulatory and financing developments for its ALS candidate CNM-Au8. The company plans to submit a New Drug Application under the accelerated approval pathway in early fourth quarter 2026, supported by biomarker and clinical data linking reductions in neurofilament light (NfL) to survival and functional outcomes in ALS patients.
In May, Clene raised $7.0 million in an underwritten registered direct common stock offering and amended two senior secured convertible debt facilities totaling $11.5 million to extend maturity to August 2027 and remove principal and interest payments before maturity. Cash and cash equivalents were $9.7 million as of June 30, 2026, and the company expects its resources to fund operations through late fourth quarter 2026.
For the quarter ended June 30, 2026, Clene generated $90 thousand in total revenue and recorded a net loss of $13.4 million, or $1.08 per share, compared with a net loss of $7.4 million, or $0.78 per share, a year earlier. Research and development expense was $3.5 million and general and administrative expense was $1.9 million. Total other expense rose to $8.1 million, driven mainly by changes in fair value of warrant and derivative liabilities and higher interest expense.